<DOC>
	<DOCNO>NCT01057225</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclophosphamide dexamethasone , work different way stop growth cancer cell , either kill cell stop dividing . Carfilzomib may stop growth cancer cell block enzymes need cell growth . Thalidomide may stop growth cancer cell block blood flow tumor . Giving combination chemotherapy together carfilzomib thalidomide may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose carfilzomib give together cyclophosphamide , thalidomide , dexamethasone treat patient newly diagnose active multiple myeloma .</brief_summary>
	<brief_title>Cyclophosphamide , Carfilzomib , Thalidomide , Dexamethasone Treating Patients With Newly Diagnosed Active Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To establish maximum tolerate dose carfilzomib give combination oral cyclophosphamide thalidomide dexamethasone . ( Phase I ) II . In newly diagnose myeloma evaluate response rate ( CR , nCR , VGPR ) carfilzomib give combination oral cyclophosphamide thalidomide dexamethasone four 28 day cycle . ( Phase II ) SECONDARY OBJECTIVES : I . Determine overall response rate ( CR , nCR , PR ) 4 , 8 , 12 cycle . II . Determine duration progression-free overall survival patient receive regimen . III . To evaluate incidence toxicity regimen . IV . To evaluate ability successfully collect peripheral blood stem cell follow four month combination therapy . OUTLINE : This phase I , dose escalation study carfilzomib follow phase II study . Patients receive carfilzomib IV day 1 , 2 , 8 , 9 , 15 , 16 ; oral cyclophosphamide day 1 , 8 , 15 ; oral dexamethasone day 1 , 8 , 15 , 22 ; oral thalidomide day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 3 month , every 3 month 1 year , every 6 month 3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion Creatinine = &lt; 2 mg/dL Calculated Creatinine Clearance &gt; = 30 mL/min Total Bilirubin = &lt; 2.0 mg/dL Alkaline Phosphatase = &lt; 3 x ULN ALT = &lt; 3 x ULN Absolute neutrophil count &gt; = 1000/uL Platelet &gt; = 75000/uL Hemoglobin &gt; = 8.0 g/dL Untreated symptomatic myeloma : Prior nonsystemic therapy treatment solitary plasmacytoma permit , &gt; = 1 month elapse last day radiation ; prior therapy clarithromycin , DHEA , anakinra , pamidronate zoledronic acid permit ; additional agent list must approve Principal Investigator Prior high dose corticosteroid therapy twelve day ( 480 mg total dose ) less permitted emergent complication newly diagnose multiple myeloma Measurable disease multiple myeloma , define least ONE following : Serum monoclonal protein &gt; = 1.0 g protein electrophoresis OR &gt; 200 mg monoclonal protein urine 24 hour electrophoresis OR serum immunoglobulin free light chain &gt; = 10 mg/dL AND abnormal serum immunoglobulin kappa lambda free light chain ratio ; OR monoclonal bone marrow plasmacytosis &gt; = 30 % ( evaluable disease ) ECOG performance status ( PS ) 0 , 1 , 2 ; ECOG PS 3 allow secondary pain opinion Investigator Willingness able provide inform write consent Negative serum pregnancy test do = &lt; 7 day prior registration , woman childbearing potential Willingness return Mayo Clinic enrol institution followup Exclusion MGUS smolder myeloma Peripheral sensory neuropathy &gt; = Grade 2 define CTEP Active Version CTCAE Active malignancy exception non melanoma skin cancer situ cervical breast cancer Pregnant woman woman reproductive ability unwilling use effective contraception Nursing woman Men unwilling use condom ( even undergone prior vasectomy ) intercourse woman , take drug 4 week stop treatment Known hypersensitivity , allergy inability tolerate agent employ Active , uncontrolled infection Severe cardiac comorbidity New York Heart Association Class III IV Heart Failure Recent history myocardial infarction six month prior registration Uncontrolled angina electrocardiographic evidence acute ischemia Severe uncontrolled ventricular arrhythmia electrocardiographic evidence active conduction system abnormalities Cardiac amyloidosis hypotension ( systolic BP le 100 mmHg ) Other concurrent chemotherapy , radiotherapy , ancillary therapy consider investigational ; NOTE : Bisphosphonates consider supportive care rather therapy , thus allow protocol treatment The following medication permit trial : investigational treatment ; cytotoxic chemotherapy ; systemic antineoplastic therapy include , limited , immunotherapy , hormonal therapy , monoclonal antibody therapy Palliative radiation therapy permit clinically indicate indicative progressive disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>